25MA023N TIL: Genetically Modified Tumor Infiltrating Lymphocytes and Methods of Producing and Using the Same
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE
The Innovation Office
InnovationMarketing@Moffitt.org
(813) 745-6828
Immunotherapies
- 23MA016 T cell engineering: Engineered Isoforms of Humanin to Improve T-Cell Therapy
- 23MA006 CAR-T: Anti-TYRP1 CAR-T for Melanoma
- 22MA088 T cell engineering: Bcl-XL Variants for Enhancing Cellular Immunotherapy Function
- 21MA005 CAR-T: CAR-Ts with Enhanced CD-28 Co-Stimulatory Domains
- 17MB043 CAR-T: CAR-T Cells with Enhanced 41BB Co-Stimulation
- 25MA026N TIL: Genetically Modified Tumor Infiltrating Lymphocytes and Methods of Producing and Using the Same
- 25MA023N TIL: Genetically Modified Tumor Infiltrating Lymphocytes and Methods of Producing and Using the Same
- 25MA022N TIL: Methods For Ex Vivo Enrichment and Expansion of Tumor Reactive T Cells and Related Compositions and Methods
- 25MA021N TIL: Methods Of Producing Tumor-Reactive T Cell Composition Using Modulatory Agents
- 24MA004N CAR-T: CD112R Based Switch Receptors For CAR-T Therapy
- 23MB038N T cell engineering: Reprogramming The CD112-CD112R Axis for Optimized CAR-T
- 23MB030N TCR: NYESO1 TCR For T-Cell Therapy and Methods of Use
- 23MB029N Vaccine: Survivin mRNA Vaccine
- 23MB026N TIL: Method Of Generating TILs from Cerebro Spinal Fluid for Leptomeningeal Disease
- 23MA021N BiTE: SSTR-Binding Bi-Specific T-Cell Engaging Molecules
- 23MA018N DC Vaccine: Methods Of Treating Leptomeningeal Disease
- 23MA009N T cell engineering: Bcl11B Sustains Multipotency and Restricts Effector Programs of Intestinal Resident Memory CD8+ T Cells
- 22MB108N Method: Leveraging L-Fucose-Mediated Signaling to Induce Monocyte-Derived Dendritic Cell Polarization
- 22MB107N TIL: Intravesical TIL Therapy in BCG Unresponsive Patients
- 22MB103N T cell engineering: Method Of Generating Cells of the T Cell Lineage with Engineering Broadly Reactive Human Notch Ligand
- 22MA082N ACT: Metabolic Reprograming of Adoptively Transferred T Cells to Potentiate Antitumor Response
- 22MA080N Method: Use of Anti-Marco Antibody with a Checkpoint Blockade Antibody for the Treatment of Cancer
- 22MA043N ACT: Targeting Myeloid-Derived Suppressor Cells (MDSCs) In Bladder Cancer to Enhance Efficacy of Adoptive Cell Therapy (ACT)
- 22MA039N TIL: Methods Of Culturing Tumor Infiltrating Lymphocytes
- 22MA026N Method: Combination Anti-4-1BB Immunotherapy, Radiotherapy, and B Cell Activation Therapy
- 22MA011N TIL: Culture Of Tumor Infiltrating Lymphocytes from Tumor Digest
- 22MA008N TCR: KRAS/Tp53 Neoantigen Specific T Cell Receptors
- 21MB097N CAR-T: CAR-T Cells with Ablated ER Stress
- 21MB073N CAR-T: Downregulating iNOS to Increase CAR-T Killing
- 21MB069N CAR-T: Chimeric Antigen Receptors with Mutated Dap10 Costimulatory Domains
- 21MA056N CAR-T: Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells
- 21MA055N Method: DNA Methylation Signatures for Predicting Response to Immunotherapy
- 21MA052N CAR-T: CAR-T Cell Therapy for Triple Negative Breast Cancer
- 21MA045N CAR-T: Differential Alternative Splicing in Relapsed and Refractory Diffuse Large B-Cell Lymphoma Patients Receiving CAR-T Therapy
- 21MA042N ACT: Inhibition Of Kir2Dl2 for the Enhancement of Adoptive Immunotherapy
- 21MA011N CAR-T: Engineered Immune Cells with Reduced Sirt6 Expression
- 20MB052N ACT: Inhibition Of Kir2Dl2 for the Enhancement of Adoptive Immunotherapy
- 20MB045N TIL: Novel CD4+ Tumor Infiltrating Lymphocytes for the Treatment of Cancer
- 20MA006N TCR: Novel T Cell Receptors (TCRs) That React to Neoantigens
- 20MA004N CAR-T: HDAC6-Inhibited Human Regulatory T Cells
- 19MB060N CAR-T: Systems And Methods for Producing Efficacious Regulatory CAR T Cells
- 19MB043N DC vaccine: HER3 Peptide Pulsed DC1 Therapy
- 17MA007 CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy
- 17MA012 TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors
- 17MA030: CD33: CAR-T Cell Constructs that Recognize CD33 for the Treatment of Acute Myeloid Leukemia
- 17MA031: CAR-T Cell Constructs that Recognize CD123 for the Treatment of Acute Myeloid Leukemia
- 17MA041 CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy
- 17MB037 Inflammasome: Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis
- 17MB042 CD99: Novel CD99 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy
- 17MB048 TILs: Method to Increase TILs by Administering Fucose to a Patient
- 18MA013 SSTR2 CAR-T: Somatostatin Receptor 2 Targeting CAR-T Cells for Neuroendocrine Tumors
- 18MA019N aAPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells
- 18MA023 NKG2D ligands: NKG2D Chimeric Antigen Receptor CAR-T Cells for Acute Myeloid Leukemia Immunotherapy
- 18MA033 TILs: TILs modified with CAR constructs result in CAR-TILs for Cancer Therapy
- 18MA034N TILs: Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma
- 18MB044N Inflammasome: Method of Using Small-molecule Pyrin-domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis
- 18MB048N TLR9 Ligand Trap: TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis
- 18MB049N Suicide Switch: CAR-T cells can be Designed to Self-Destruct if Patient shows signs of Toxicity including graft-vs.-host-disease, cytokine release syndrome (CRS), and neurotoxicty
- 18MB054 Glioma Stem Cell Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers
- 18MB059 Brain Mets: CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers that Recognize Lung Cancer Brain Metastases
- 18MB061 Antibodies: Fully Human anti-PD1 Antibodies
- 18MB062N Antibodies: Fully Human anti-LAG3 Antibodies
- 18MB072 Method of using anti-CD277 antibodies to treat cancer
- 18MB078 TILs: Enhancing the anti-tumor immunity of TILs by inhibiting Sirt2
- 19MA007 B-RAF: Combination Therapy of TILs and BRAF Inhibitors to Treat BRAF Inhibitor-Resistant Metastatic Melanoma
- 19MA015N GPC3: Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1
- 19MA015NT2 NKG2D-Ligand: Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1
- 19MA022N aAPC: Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing anti-NKG2D CAR-T Cells
- 19MA026N: NOTCH: Enhancing the Efficacy of Adoptive T-cell Immunotherapy Using Novel Notch Ligands
- 19MA029N Bispecific T-Cell Engagers: B Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Half Lives
- 19MA033N EGFR, MUC1: Bispecific CAR-T Cell constructs (chimeric antigen receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer
- 19MA035N T-bet: T-bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence
- 19MB047N Antibodies: Fully Human anti-TSPAN7 Antibodies
- 19MB048N Antibodies: Fully Human anti-BDNF Antibodies
- 19MB049N Fucose increases tumor cell HLA-DRB1 expression increasing CD4+ T-cell activation with synergistic tumor killing activity with anti-PD1 checkpoint inhibitors
- 19MB066T2 N-Terminal Mutant PGC-1α Overexpression Enhances Metabolic Fitness Reducing CAR-T Exhaustion while Maintaining Proliferative Capacity
- 20MA005: PERK, IRE1: Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors
- 20MA009 CAR-T: D99/CLEC12A AND gated Bispecific CAR-T for the Treatment of AML
- 20MA013N: TILs: 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes
- 20MA016N: HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic
- 20MA024 CD33 CD123: Novel Bispecific CD33 CD123 scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy
- 20MA027 Olfactory Receptor Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Solid Tumors
- 20MB050N Bispecific Gamma Delta CAR-T Cells that Recognize CD33, CD123 and NKG2D Ligands for the Treatment of Acute Myeloid Leukemia
- 20MB053N Single-domain antibodies (nanobodies) targeting the notch ligand DLL4 to Disrupt the interaction of DLL4 and Notch1 for GVHD
- 20MB062 Mutated Estrogen Receptor Neoantigen Peptide
- 21MA008N Human ITAM Mutated Variants For Better Intracellular Signaling Domains For Gamma-Delta CAR T-Cell Activation
- 21MA028N MDSC: Method of using Oral-L-Fucose to reduce immunosuppressive effect of Myeloid Derived Suppressor Cells (MDSCs)
- 21MB061 KRAS: Platform Technology: Dimeric IgA Therapeutic Antibody for Intra-Tumoral Targeting of Mutant KRAS
- 21MB064 CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy
- 21MB083 TILs: aAPCs that expresses an anti-CD3 scFv transmembrane to determine the cytotoxicity of TILs
- 22MB110N DC Vaccine: Enriching Monocyte Derived Dendritic Cells to Create DC Vaccine based Immunotherapy Using L-Fucose